Epigenomics AG (FRA:ECX) Total Liabilities: €11.61 Mil (As of Dec. 2025)

What is Epigenomics AG Total Liabilities?

Epigenomics AG FRA:ECX +9.20% 13 Total Liabilities is €11.61 Mil as of Dec. 2025. GuruFocus rates FRA:ECX with a GF Score™ of 13/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Epigenomics AG's Total Liabilities for the quarter that ended in Dec. 2025 was €11.61 Mil.

Epigenomics AG's quarterly Total Liabilities increased from Dec. 2024 (€11.85 Mil) to Jun. 2025 (€11.86 Mil) but then declined from Jun. 2025 (€11.86 Mil) to Dec. 2025 (€11.61 Mil).

Epigenomics AG's annual Total Liabilities declined from Dec. 2023 (€12.85 Mil) to Dec. 2024 (€11.85 Mil) and declined from Dec. 2024 (€11.85 Mil) to Dec. 2025 (€11.61 Mil).

Epigenomics AG Total Liabilities Related Terms

Epigenomics AG Total Liabilities Historical Data

* Premium members only.

The historical data trend for Epigenomics AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epigenomics AG Total Liabilities Chart

Epigenomics AG Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

2.54

13.99

12.85

11.85

11.61

Epigenomics AG Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Total Liabilities	Get a 7-Day Free Trial															12.85	12.04	11.85	11.86	11.61

13GF Score

Epigenomics AG FRA:ECX

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Epigenomics AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Epigenomics AG's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.004	+	(11.381	+	0.228
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	11.61

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	11.615	-	0.002
	=	11.61

Epigenomics AG's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.004	+	(11.381	+	0.228
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	11.61

Total Liabilities	=	Total Assets (Q: Dec. 2025 )	-	Total Equity (Q: Dec. 2025 )
	=	11.615	-	0.002
	=	11.61

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of €11.61 Mil mean?

Epigenomics AG (FRA:ECX) has a Total Liabilities of €11.61 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Epigenomics AG and its competitors.

Is Epigenomics AG's Total Liabilities too high?

Epigenomics AG's current Total Liabilities is €11.61 Mil. Overall, Epigenomics AG has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Epigenomics AG's Total Liabilities compare to TMO and DHR?

Epigenomics AG's Total Liabilities of €11.61 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Medical Diagnostics & Research company?

A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Epigenomics AG and its competitors. Epigenomics AG's current Total Liabilities is €11.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Epigenomics AG stock overvalued right now?

Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.95 — trading 955.6% above its estimated fair value. The current Total Liabilities is €11.61 Mil. Epigenomics AG's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current Total Liabilities is €11.61 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Epigenomics AG (FRA:ECX) Overvalued in 2026?

Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued. The current stock price of €0.95 is trading 955.6% above its estimated GF Value™ of €0.09. GuruFocus considers Epigenomics AG to be Significantly Overvalued.

Key valuation signals for FRA:ECX:

Total Liabilities: €11.61 Mil
GF Value™: €0.09 vs. price of €0.95 (955.6% above fair value)
GF Score™: 13/100 with 3 warning signs

No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Epigenomics AG Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies TMO DHR SHSE:603259 XSWX:LONN IDXX A NTRA WAT IQV ILMN MTD DGX LH GH MEDP XPAR:ERF ICLR RVTY CRL XPAR:BIM

Other Exchanges ECX:Germany

Address Ziegelhauser Landstrabe 3, Heidelberg, BW, DEU, 69120

Website https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

13GF Score

Get the complete analysis for FRA:ECX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.95

Price

€0.09

GF Value

View FRA:ECX Analysis

See Total Liabilities data for all stocks →